Rybelsus for Weight Loss in 2026: Replaced by Ozempic Tablets and the Wegovy Pill

Rybelsus, the original semaglutide pill, was never approved for weight loss, and in the U.S. it no longer exists under that name: on May 4, 2026 it was replaced by Ozempic tablets, which are also approved only for type 2 diabetes. If you want a semaglutide pill for weight loss, the product designed for it is the Wegovy pill, a higher-dose oral semaglutide approved for chronic weight management in December 2025.

Here's what happened to Rybelsus, how much weight people lost on it, and what to ask for instead.

For weight loss specifically, the oral semaglutide option is now the Wegovy pill. See Wegovy pill vs injection for how it compares with the weekly shot.

Rybelsus was approved in 2019 to lower blood sugar in adults with type 2 diabetes. Its top dose was set for glucose control, and people in its PIONEER trials lost a modest amount of weight, typically a few kilograms. That's helpful for someone with diabetes, but it's far less than the 13% to 15% average seen with the weight-loss doses of semaglutide.

Using Rybelsus or Ozempic tablets purely for weight loss is off-label, and insurers almost never cover it without a diabetes diagnosis.

Novo Nordisk reformulated its diabetes pill and rebranded it as Ozempic tablets, launched nationwide on May 4, 2026. The new strengths, 1.5 mg, 4 mg and 9 mg, aren't milligram-for-milligram the same as the old Rybelsus doses, so switching follows the prescriber's conversion. Outside the U.S., Rybelsus is still sold in many countries.

The Wegovy pill uses the same molecule at a much higher dose, 25 mg once daily, with the same strict routine: take it first thing in the morning on an empty stomach with a small sip of water, then wait 30 minutes before eating, drinking or taking other medicines. In the OASIS 4 trial, people without diabetes lost about 13.6% of their body weight over 64 weeks, close to the 15% seen with the Wegovy injection.

There's also Foundayo (orforglipron), a non-peptide GLP-1 pill approved in April 2026 that doesn't require fasting; average weight loss was about 11% to 12% at its higher doses. For all the options, see GLP-1 patches vs pills and which GLP-1 is best for weight loss.

All oral semaglutide products cause the same side effects as the injections, mainly nausea, diarrhea, vomiting and constipation, most often while the dose is increasing. Taking them incorrectly, for example with a full glass of water or food, sharply reduces how much drug is absorbed, which is the most common reason the pill seems not to work.

Rybelsus was a diabetes pill with modest weight effects, and in the U.S. it's been replaced by Ozempic tablets. For weight loss, the semaglutide pill to ask about is the Wegovy pill, which produced about 13.6% average weight loss and costs $149 to $299 a month self-pay. See our Wegovy cost guide and dosing schedule.